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INTRODUCTION
Graft-versus-host disease (GVHD) is a signiﬁcant com-
plication of allogeneic hematopoietic transplantation and of
bone marrow transplantation (BMT). Even when the donor
and recipient are genotypically identical at the major trans-
plantation (HLA) loci, the incidence of acute GVHD is
10% to 40%, which has been attributed to differences in
minor histocompatibility antigens (mHags) [1-6]. Human
mHags have been difficult to identify. Evidence has been
presented, however, for several candidate molecules,
including the platelet–endothelial-cell adhesion molecule
PECAM-1, or CD31, a 120-to-130–kd membrane glyco-
protein now known to have several codons with single
nucleotide polymorphisms (SNPs) (Table 1) [7-12].
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ABSTRACT
Graft-versus-host disease (GVHD) complicating allogeneic bone marrow transplantation (BMT) is often attributed
to mismatched minor histocompatibility antigens (mHags), which are poorly defined in humans. CD31 is a candidate
human mHag relevant to acute GVHD, but reports disagree about its level of significance, the role of HLA restric-
tion, and the relative importance of different polymorphic codons within the molecule. We therefore examined in
greater detail the impact of CD31-matching on BMT outcome in a prospective study from a single institution. Sam-
ples of recipient and donor DNA were collected pretransplantation for all patients receiving unmanipulated bone
marrow from an HLA-identical sibling over a 45-month period at our institution. CD31 DNA typing of alleles at the
3 polymorphic codons 125 (L or V), 563 (N or S), and 670 (R or G) was performed for 118 patient-donor pairs plus
2 additional pairs who had codon 125 typing only. Donor-recipient CD31 nonidentity was tested for correlation with
BMT clinical outcome measures of severe acute GVHD, chronic GVHD, relapse, and survival. Gene frequencies of
approximately 0.5 for each allele at all 3 codons were comparable to previous reports. Because complete association
was seen for 563N with 670G and for 563S with 670R, nonidentity for those codons was analyzed as a single genetic
marker designated codon 563/670. Donor-recipient CD31 nonidentity was a significant risk factor for overall sur-
vival, both at codon 563/670 (hazard ratio [hr] = 2.58, P = .005) and at codon 125 (hr = 1.07, P = .036). Similar results
held for disease-free survival. Nonidentity at codon 563/670 was also a significant risk factor (odds ratio [OR] = 11.15,
P = .011) for severe (grades III, IV) versus no (grade 0) acute GVHD. Nonidentity at codon 125 posed less but still
significant risk (OR = 9.30, P = .030). When the comparison group without severe acute GVHD was expanded to
include grade I as well as grade 0 patients, the risk from CD31 nonidentity increased for both codon 563/670 (OR =
12.31, P = .010) and codon 125 (OR = 11.24, P = .011). CD31 nonidentity remained a significant independent risk fac-
tor for survival and for severe acute GVHD when tested in multivariate analysis with the covariates of adulthood,
recipient-donor sex difference, ethnic group, disease, pretransplantation risk category, HLA-A2 type, B44-like types,
and GVHD prophylactic regimen. CD31 nonidentity showed a trend but failed to achieve statistical significance as a
risk factor for relapse and for chronic GVHD. In conclusion, donor-recipient CD31 nonidentity is a significant risk
factor for survival and for severe acute GVHD in HLA-identical sibling BMT. The stronger associations with codon
563/670 suggest that polymorphism may be more important than the linked polymorphism at codon 125.
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Behar et al. [8] demonstrated the ﬁrst CD31 polymor-
phism, at codon 125, and examined its effect on outcome in
HLA-identical sibling BMT. Specifically comparing
patients with severe acute GVHD to those with none, these
researchers reported that 71% of patients with grade III or
IV disease showed nonidentity to their donor at CD31
codon 125 versus only 22% of patients with grade 0 disease
(odds ratio [OR] = 8.93, P = .002). Using a multicenter data-
base, Nichols et al. [13] subsequently reported that CD31
nonidentity at codon 125 was slightly higher among patients
with grade III/IV (37%) than those with grade 0 disease
(31%) (OR = 1.30), but that difference was not statistically
significant. Among their HLA-A2 positive patients, how-
ever, the difference in CD31 codon 125 nonidentity fre-
quencies was significant (P = .03); 42% for grade III/IV
versus 21% for grade 0 patients (OR = 2.67). In a later multi-
center Japanese study, Maruya et al. [10] discovered addi-
tional CD31 polymorphic codons (563 and 670) and examined
CD31 incompatibility (nonidentity was not reported) as a
risk factor for grades I to IV versus grade 0 disease. Com-
plete concordance existed between S563N and R670G, and
those codons were treated together as a single parameter,
codon 563/670. Their patients were subdivided into HLA
“superfamily” groups based on similarities of the peptide
binding motif of their HLA class I antigens. Among patients
with HLA-B44–like superfamily HLA antigens (includes
HLA-B37, 41, 44, 45, 47, 49, 50, 60, and 61), incompatibil-
ity at CD31 codon 563/670 was a signiﬁcant risk factor for
acute GVHD grades I to IV (OR = 8.9, P = .003), whereas
codon 125 incompatibility showed a similar trend with half
that risk but fell short of attaining statistical significance
(OR = 4.5, P = .09). Among their patients in the HLA-
A2–like superfamily group (includes all HLA-A2, A68, and
A69 except A*0207, A*6802, and A*6901), incompatibility at
either codon 125 or 563/670 was not a signiﬁcant risk factor
for grades I to IV disease.
The 3 acute GVHD studies cited above suggest differ-
ing interpretations for a possible mHag role for CD31 poly-
morphism, eg, codon 125 in all HLA types versus codon
125 in only HLA-A2+ patients versus codon 563/670 in only
B44-like superfamily patients. To address this issue, we
elected to reevaluate the role of CD31 polymorphism in
BMT by prospectively studying its impact on acute GVHD
and other outcome measures among our recent patients.
The results of this single transplantation center study show
that CD31 nonidentity is a signiﬁcant risk factor not only
for acute GVHD but also for survival, consistent with the
interpretation that CD31 is a strong candidate for a clini-
cally important mHag.
MATERIALS AND METHODS
Patients
All protocols were approved by the Institutional Review
Board at Stanford University, and informed consent was
obtained from each subject or appropriate parent or guardian.
For all HLA-identical sibling BMTs performed at our institu-
tion from January 30, 1996 to October 31, 1999 (ie, not over-
lapping with the transplantations reported by Behar et al.)
using unmanipulated marrow, DNA was obtained prospec-
tively as residual material from HLA typing of each patient
and donor at the time of pretransplantation evaluation. DNA
was qualitatively and quantitatively adequate for CD31 typing
of both donor and recipient for 120 BMT pairs: 118 pairs
were typed for codons 125, 563, and 670, and 2 additional
pairs had DNA sufﬁcient to perform typing for codon 125
only. Relevant characteristics of the 120 CD31-typed donors
and patients are summarized in Table 2. Patients ranged in
age from 1 to 60 years (mean, 28.6 years).
All patients and donors were HLA-AB typed by stan-
dard lymphocyte microcytoxicity using well-characterized
antisera and were HLA-DR typed by molecular (DNA)
methods [14], both at levels of resolution sufﬁcient to assure
HLA genotype identity. Based on general clinical condition
and disease status at the time of BMT, categorization of
anticipated overall transplantation risk was made for each
patient immediately prior to transplantation. Patients with
diagnoses of chronic myelogenous leukemia in chronic or
accelerated phase, acute lymphocytic leukemia or acute
myeloid leukemia in first complete remission (CR), non-
Hodgkin’s lymphoma in first CR, or in the nonmalignant
diagnostic group (except myelodysplastic syndrome) were
categorized as low risk (category “Low”). All other patients
were categorized as high risk (category “High”).
Pretransplantation conditioning regimens were those
typically used at this institution and were based on each
patient’s original diagnosis and pretransplantation clinical
status [15]. Standard posttransplantation GVHD prophylac-
tic regimens consisted of combinations of cyclosporine,
methotrexate, and/or prednisone as typically used according
to each patient’s original diagnosis and pretransplantation
status [2,15]. The numbers of patients receiving each drug
combination are shown in Table 2. The diagnosis and grad-
ing of acute and chronic GVHD were established by attend-
ing transplantation physicians following previously published
clinical criteria [4,16,17], with conﬁrmatory tissue biopsies
performed whenever possible. Patients who had no (grade 0)
Table 1. Allele-Speciﬁc Reactivity of CD31 Probes*
Probe Specificity† OD Versus Target Genotypes‡
125 V/V 125 L/L 125 L/V
125 V (GTG) 1.229 0.012 0.782
125 L (CTG) 0.016 1.193 0.693
563 S/S 563 N/N 563 S/N
563 S (AGC) 0.491 0.071 0.324
563 N (AAC) 0.015 1.035 0.596
670 G/G 670 R/R 670 G/R
670 G (GGA) 1.070 0.065 0.563
670 R (AGA) 0.055 0.597 0.265
*OD indicates optical density.
†Probe speciﬁcity is given as codon number and amino acid, with
the corresponding nucleic acid sense strand triplet in parentheses and
the single nucleotide polymorphisms underlined. For amplicons con-
taining codon 125 or 670, the reverse strand was biotinylated and cap-
tured; for codon 563 amplicons, the forward strand was biotinylated
and captured.
‡ODs in sequence-specific oligomer probe–enzyme-linked
immunoassay (SSOP-ELISA) testing of allele specific probes against
individuals’ CD31 amplicons in which the genotypes were veriﬁed by
sequencing.
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or minimal (grade I) dermal, gut, or hepatic signs or symp-
toms of GVHD within the ﬁrst 100 days posttransplantation
were considered not to have severe acute GVHD. Patients
who had substantial and typical rashes, diarrhea, or hyper-
bilirubinemia (ie, grade III or IV) within that same time
frame were considered to have severe acute GVHD,
whereas patients with milder, less clear-cut signs and symp-
toms (ie, grade II) were considered to have equivocal severe
acute GVHD. Patients who had signs of extensive chronic
GVHD beyond 100 days posttransplantation were tabulated
as having chronic GVHD, whereas patients who had only
limited or no signs were considered not to have chronic
GVHD. The diagnosis of relapse was documented histolog-
ically and/or cytogenetically.
CD31 Typing
All CD31 typing was performed independent of and
blinded with respect to patient characteristics, conditioning
regimens, GVHD prophylaxis, and clinical outcomes.
Genomic DNA was extracted from peripheral blood leuko-
cytes of each patient and donor, using commercial DNA iso-
lation kits per manufacturer’s directions (Gentra Systems,
Minneapolis, MN). The CD31 gene sequences (GenBank
accession numbers M28526, L34640, and L34644) were used
to design primer sets capable of generating amplicons from
genomic DNA that would each encompass a codon of inter-
est. The alleles of interest and their previously reported
[8,10,13] approximate gene frequencies are: in exon 3, codon
125 L (.52) or V (.48); in exon 8, codon 563 S (.52) or N (.48);
and in exon 12, codon 670 G (.48) or R (.52). An additional
polymorphism V → M at codon 80 in exon 3 was not studied
because it is rarely observed [10]. We used 5′ biotin (B)-
labeled primers (Operon, Alameda, CA) to generate poly-
merase chain reaction (PCR) amplicons for a sequence-
specific oligomer probe–enzyme-linked immunoassay
(SSOP-ELISA) [14] to type each CD31 allele. Some primers
carried a 20-bp M13-reverse oligomer (M13-Rev) 5′ tag for
use as a sequencing primer site. A 259-bp amplicon contain-
ing codon 125 was produced in a 25-µL PCR with 25 ng
genomic DNA, forward primer 5′AAG AAC CTG ACC
CTG CAG TGC TTC (80 mmol/L), and reverse primer 5′B-
TCC TGT GCT CAG TTC CAA GGA CT (40 mmol/L) in
buffer containing 0.25 U Taq polymerase (Amplitaq, Perkin
Elmer, Foster City, CA) mixed 1:1 with anti-Taq antibody
(Clontech, Palo Alto, CA), 1.5 mmol/L MgCl2, 10 mmol/L
Tris-HCI, pH 8.3, and 250 nmol/L deoxynucleoside triphos-
phates [dNTPs] (Perkin Elmer). Thirty-ﬁve cycles of 95°C ×
20 seconds, 60°C × 1 minute, and 72°C × 20 seconds were
followed by a ﬁnal extension at 72°C × 10 minutes. A 236-bp
amplicon containing codon 563 was produced by a 20-µL
PCR using 75 ng genomic DNA in the preceding buffer but
with 0.5 U Taq with 1:1 anti-Taq, forward primer 5′B-TGC
AAT GTC CTG TGA ATG AAG G, and reverse primer
5′M13-Rev-TTT GCT TCT GGG GAC ACT GGA G,
both at 100 nmol/L, and a “touchdown” program of 15 cycles
starting at 95°C × 30 seconds and annealing at 59°C ×
60 seconds, dropping the annealing temperature 1°C/cycle,
followed by 18 cycles of 95°C × 30 seconds and 44°C ×
60 seconds, with a final extension of 44°C × 2 minutes. A
237-bp amplicon for codon 670 was also generated in a
20-µL PCR with 75 ng genomic DNA and the same touch-
down program, but with a buffer of 0.5 U Taq with 1:1 anti-
Taq, 1.5 mmol/L MgCl2, 60 mmol/L Tris-HCI, pH 9.0,
15 mmol/L (NH4)2SO4, 250 nmol/L dNTPs, forward
primer 5′M13-Rev-CTA GAA TTT CCC TTG TCA
CTC ACC C, and reverse primer 5′B-GGG TCA TTA
AGA GAG GTG GG, each at 60 nmol/L.
Table 2. Patient Characteristics*
Severe Acute
Total No. of GVHD†
Patient Characteristics Patients No Yes P Value
Pretransplantation
Adulthood .27‡ 
<18 years 41 35 1 
≥18 years 79 66 8
Sex (donor/recipient) .22§
M/M 40 33 5
F/F 21 18 1
F/M 30 28 0
M/F 29 22 3 
Ethnicity .35§
Asian-Pacific Islander 15 13 1
Black 5 4 1
Caucasian 74 62 7 
Hispanic/Latino 26 22 0
Pretransplantation risk .50‡
category
Low 69 58 4
High 51 43 5
Diagnostic group .65§ 
ALL 26 24 1
AML 29 24 2
CML 29 25 2
MDS/Thal/Misc 25 20 2
NHL/CLL/MM/other 11 8 2
HLA-A2 antigen .50‡
Positive 62 52 6
Negative 58 49 3
HLA-B44 antigen .16‡
Positive 52 39 6
Negative 68 62 3
Posttransplantation
GVHD prophylaxis .33§ 
MC 61 51 3
MCP 32 28 2
CP 24 19 4
M 3 3 0
*GVHD indicates graft-versus-host disease; ALL, acute lympho-
cytic leukemia; AML, acute nonlymphocytic leukemia; CML, chronic
myelogeneous leukemia; MDS, myelodysplastic syndrome; Thal, tha-
lassemia; Misc, miscellaneous nonmalignancy; NHL, non-Hodgkin’s
lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple
myeloma; M, methotrexate; C, cyclosporine; P, prednisone.
†No = Grade 0/I; Yes = Grade III/IV; the 9 Grade II patients are
excluded.
‡Fisher exact test for severe acute GVHD, yes versus no.
§Chi-square test for severe acute GVHD, yes versus no.
Diseases represented in <10% of the patients were clustered with
others having some related characteristic; eg, premalignant and nonma-
lignant diseases formed one cluster. Patient diagnostic groups were
ALL; AML; CML; NHL, CLL, MM, or other malignancy; and MDS,
Thal, or miscellaneous nonmalignancy.
F.C. Grumet et al.
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SSOP-ELISA was performed as previously described
[14]. Brieﬂy, amplicons were denatured and added to strep-
tavidin (SA) (Sigma, St. Louis, MO) coated wells of
microtiter trays (Costar, Corning, Corning, NY) preloaded
with 5′ fluorescein-tagged oligomer probes (Operon)
designed to be allele specific in a controlled stringency
wash. Following hybridization at 56°C × 10 minutes and a
38°C stringency wash, alkaline phosphatase–conjugated
antifluorescein Fab antibody fragment (Boehringer-
Mannheim, Mannheim, Germany) was added to detect
hybridization of the specific probe to the SA-captured
biotinylated strand of amplicon. Wells were then washed in
a low-stringency salt/sodium phosphate/EDTA (SSPE)
buffer, after which substrate and ampliﬁer (ELISA Ampliﬁ-
cation System, Gibco BRL, Rockville, MD) were added and
probe reactivity was quantiﬁed by measuring optical density
at 490 nm (650 nm reference) in a microplate reader
(Molecular Devices, Sunnyvale, CA). Probe discrimination
among alleles at each codon position was validated by test-
ing amplicons of individuals with different genotypes proven
by sequencing. Amplicons from sequenced individuals were
also included as positive and negative controls to validate
every set of ELISA-SSOP plates.
For each allele, the probe (polymorphic position shown
in bold and underlined) and its 38°C controlled stringency
wash conditions with SSPE were: codon 125L, 5′GAG TAC
CAT CTG TTG GTG, 0.4× SSPE; codon 125 V, 5′AC
CAG GTG TTG GTC GAA G, 0.4× SSPE; codon 563S,
5′TG TTC CTT CCT AGC CTT C, 0.1× SSPE; codon
563N, 5′TG TTC CTT CTT AGC CTT C, 0.1× SSPE;
codon 670G, 5′GAC GAT GTG GGA AAC CAT, 0.1×
SSPE; codon 670 R, 5′AC GAT GTC ACA AAC CAT G,
2.1× SSPE. Examples of the allele speciﬁcity of the probes
are shown in Table 1.
When CD31 incompatibility was determined, it was
always defined in the GVHD direction. A BMT pair was
thus deemed GVHD incompatible for a particular CD31
codon when the recipient possessed any allele (of that
codon) that was absent from the donor. All other donor-
recipient CD31 combinations were designated GVHD
compatible.
Population Genetics and Statistical Analysis
Standard population genetics formulae were applied to
observed phenotypes to obtain gene frequencies, expected
phenotype frequencies, and goodness of fit to Hardy-
Weinberg equilibrium [18-20]. Haplotype frequencies were
derived from observed phenotypes, and 2-point linkage
disequilibrium for any pair of codons was measured by the
difference (∆) between observed and expected haplotype fre-
quencies [21,22]. The relative ∆ (∆r) for any haplotype was
then calculated as ∆/∆max, where ∆max is the theoretical maxi-
mum ∆ possible for that haplotype.
Graphs of Kaplan-Meier survival curves; calculations for
chi-square tests, Fisher exact test, logistic and Cox regres-
sion, and proportional hazards models were performed with
the Stata computer program (Stata Press, College Station,
TX). P values for the tests were reported and statistical sig-
niﬁcance noted at the 2-tailed 5% level.
RESULTS
Population Genetics 
For population genetics analyses, 124 randomly selected
DNA samples from unrelated BMT candidates had com-
plete phenotyping at all 3 CD31 polymorphic codons and
served as a population selected without regard to CD31
type. The observed CD31 phenotypes and the derived gene
frequencies for alleles at each codon are shown in Table 3.
At each codon position, phenotype frequencies were a good
ﬁt for Hardy-Weinberg equilibrium. Two-point linkage dis-
equilibrium was measured between the polymorphic codons,
beginning with combinations of alleles at codons 563 and
670. The haplotype 563S/670R had a ∆r = 1.0, as did haplo-
type 563N/670G. No individuals were observed who were
563S+/670R–, 563S–/670R+, 563N+/670G–, or 563N–/670G+.
Because of the 1:1 concordances of 563S with 670R and of
563N with 670G, for all further analytic purposes the
563S/670R pair is treated as a single genetic marker, as is
the 563N/670G pair; this single marker is designated codon
563/670. Less but still substantial linkage disequilibrium was
shown for 125L with 563S/670R (∆r = .943) and for 125V
with 563N/670G (∆r = .923). There was a strong correla-
tion (P < .001) observed in BMT donor-recipient pairs
between identity at codon 125 and identity at codon
563/670: there were 59 pairs identical at both, 48 not iden-
tical at both, 4 identical at codon 125 but not at 563/670,
7 identical at codon 563/670 but not at 125, and 2 identical
at codon 125 but not typed for codon 563/670. The lack of
1:1 concordance between any codon 125 allele and any
563/670 allele, as well as the lack of 1:1 concordance
between donor-recipient identity at codon 125 and identity
at 563/670, led us to analyze codons 125 and 563/670 sepa-
rately as genetic risk factors in BMT.
Table 3. Observed CD31 Phenotypes
CD31 Phenotype Number in Each Ethnic Group
Asian/
Codon 125 V/L Codon 563 S/N Codon 670 R/G Pacific Islander Black Caucasian Hispanic/Latino
+/– +/– +/– 0 1 0 0
+/– +/+ +/+ 0 0 3 1
+/– –/+ –/+ 7 1 23 2
+/+ +/– +/– 1 1 7 3
+/+ +/+ +/+ 7 1 32 10
–/+ +/– +/– 1 1 11 11
Gene frequency .55/.45 .52/.48 .52/.48
CD31 and BMT Outcome
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Acute GVHD
Acute GVHD rates among the 120 patients were grade
0 = 66.7%, grade I = 17.5%, grade II = 8.3%, grade III =
1.7%, and grade IV = 5.8%. The relation of severe acute
GVHD to CD31 nonidentity is shown in Table 4.
Severe (Grade III/IV) Versus No (Grade 0) Acute
GVHD. The same comparative groupings as originally
reported in Behar et al. and Nichols et al. are shown in the
center columns of Table 4. By that comparison (ie, grade
III/IV versus grade 0), for patients of all HLA types in the
current study, severe acute GVHD was significantly more
frequent (OR = 9.30, P = .030) among codon 125 nonidenti-
cal transplant recipients than identical transplant recipients.
Furthermore, because Nichols et al. found codon 125 non-
identity to be a significant risk factor for severe acute
GVHD among HLA-A2+ patients, we examined the HLA-
A2+ subset of our patients. In that subset, we observed a sim-
ilar, but not statistically significant, risk (OR = 6.39, P =
.097) from codon 125 nonidentity. Because of the report of
Maruya et al. implicating codon 563/670 polymorphism in
acute GVHD of any grade, particularly for patients with
HLA-B44–like types, we also examined the effect of non-
identity at that codon as a risk factor in severe acute
GVHD. Among patients of all HLA types, nonidentity at
codon 563/670 was a somewhat stronger risk (OR = 11.15,
P = .011) than was nonidentity at codon 125. Signiﬁcant risk
from 563/670 nonidentity was also seen among the subset of
patients with B44-like types (OR = , P = .019). The num-
ber of severe acute GVHD patients discordant at the 2
codons (ie, 1 patient identical with his donor at codon 125
but nonidentical at 563/670 and 1 vice versa) was too small
to yield further useful information. To further facilitate ref-
erence to Maruya et al., we also examined the risk for grade
III/IV versus grade 0 from GVHD incompatibility (rather
than nonidentity) at 563/670 and observed it to be less
impressive than nonidentity, but still significant, both in
patients of all HLA types (OR = 6.33, P = .013) and in the
B44-like subset of patients (OR = 6.67, P = .049).
Severe (Grade III/IV) Versus Minimal (Grade 0/I)
Acute GVHD. Because grade I acute GVHD is a relatively
minor disease and because the survival curves (data not
shown) of grade 0 and grade I patients at Stanford has not
differed signiﬁcantly, we also analyzed the grade 0 and grade
I patients combined to serve as the group designated as with-
out severe acute GVHD. Results of tabulating grade III/IV
versus grade 0/I can be seen in the columns on the right side
of Table 4. For every comparison, CD31 nonidentity yielded
equal or greater risk that was always more statistically signiﬁ-
cant than the cognate comparison using only grade 0 patients
as the group without severe disease. The 10 grade II patients
were considered diagnostically difficult and ambiguous, as
reﬂected by the fact that their group overall survival curve
(not shown) completely overlapped that of the grade 0/I
group (hazard ratio [hr] = 0.84, P = .644) but differed signiﬁ-
cantly (hr = 6.71, P = .019) from that of the grade III/IV
group. Therefore, because of the uncertainty of whether or
not grade II patients should be included in the designation of
severe acute GVHD, at this point we elected to limit detailed
comparisons to only the clearly differentiated groups of
grade III/IV versus grade 0/I. (Alternatively, we could have
instead broadened the severe acute GVHD group to include
the 5 CD31 identical and 5 nonidentical grade II patients. In
that case, comparison of the resultant moderate-severe
[grade II/IV] group of patients versus the minimal [grade
0/I] patient group still shows nonidentity at both codon 125
[OR = 3.04, P = .044] and codon 563/670 [OR = 3.33, P =
.024] to be signiﬁcant risk factors for acute GVHD among
patients of all HLA types). Although the 10 grade II patients
were excluded here from analyses of severe acute GVHD,
they were not excluded from analyses of the other BMT out-
come measures of relapse, chronic GVHD, or survival.
Any (Grade I-IV) Versus No (Grade 0) Acute GVHD
Among B44-Like Patients. To again facilitate reference to
the report of Maruya et al., the B44-like subset of patients
with grades I to IV acute GVHD were compared with those
with grade 0, examining GVHD incompatibility as well as
nonidentity at codon 563/670. Nonidentity showed a trend
as a risk factor for the broad category of any grade of
GVHD (OR = 1.55, P = .577), but incompatibility did not
(OR = 0.874, P = .765); neither was statistically signiﬁcant.
Table 4. Severe Acute GVHD and CD31 Nonidentity*
CD31 Codon Grade III/IV Versus Grade 0 OR P Grade III/IV Versus Grade 0/I OR P
All HLA types 9.30 .030 11.24 .011
Identical 125 1 43 1 59
Nonidentical 125 8 37 8 42
HLA-A2+ only 6.39 .097 9.44 .032
Identical 125 1 23 1 34
Nonidentical 125 5 18 5 18
All HLA types 11.15 .011 12.31 .010
Identical 563/670 1 46 1 60
Nonidentical 563/670 8 33 8 39
HLA-B44–like ∞ .019 ∞ .007
Identical 563/670 0 17 0 24
Nonidentical 563/670 6 12 6 15
HLA-A2+ ∞ .005 ∞ .002
Identical 563/670 0 26 0 36
Nonidentical 563/670 6 15 6 15
*GVHD indicates graft-versus-host disease; OR, odds ratio.
F.C. Grumet et al.
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Other Variables. As seen in Table 2, the independent
7 pretransplantation and 1 posttransplantation patient char-
acteristics listed were each tested for association with severe
acute GVHD (grade III/IV versus 0/I). Expected trends were
present for the generally accepted risk factors (eg, risk cate-
gory, adulthood), but none attained statistical significance,
presumably because of the small number of affected patients.
Together with codon 125 nonidentity, all were then used as
covariates in a log-rank (Cox) analysis, using time to onset of
severe acute GVHD. In this multivariate analysis, only
codon 125 nonidentity was a statistically signiﬁcant risk fac-
tor (hr = 1.28, P = .025). Similarly, multivariate analysis was
performed for codon 563/670 nonidentity together with the
same 8 independent characteristics cited above, showing only
nonidentity at codon 563/670 to be statistically signiﬁcant
(hr = 17.11, P = .012) as a risk factor for severe acute GVHD.
Survival
Kaplan-Meier survival curves for CD31 identical and
CD31 nonidentical BMT patients were plotted without
regard to acute GVHD assignment and were compared
under Cox regression.
Overall Survival. For overall survival in patients of any
HLA type (Figure, A and D), CD31 nonidentity was a
signiﬁcant risk factor at both codon 125 (hr = 1.07, P = .036)
and codon 563/670 (hr = 2.58, P = .005). Among HLA-A2+
patients (Figure, B and E), codon 125 nonidentity showed a
trend but did not achieve signiﬁcance as a risk factor; how-
ever, codon 563/670 nonidentity again posed a significant
risk (hr = 3.51, P = .005). Among patients with B44-like
types (Figure, C and F), nonidentity at either CD31 codon
showed only a nonsigniﬁcant trend as a risk factor.
Disease-Free Survival. For disease-free survival among
patients of all HLA types, Kaplan-Meier curves yielded simi-
lar graphs (not shown) to those seen for overall survival, both
for codon 125 (hr = 1.07, P = .032) and for codon 563/670
(hr = 2.50, P = .004). For disease-free survival among the
HLA-A2+ and among the B44-like patients, the effects of
CD31 nonidentity (data not shown) were essentially the same
as were observed for overall survival in those patient groups.
Incompatibility and Survival. To again facilitate refer-
ence to Maruya et al., we tabulated overall survival (at the
close of the study) as a function of codon 563/670 incompat-
ibility. For the B44-like subset of patients, overall survival
was 60% for incompatible versus 76% for compatible (n =
52, OR = 2.07, P = .318); whereas for patients of all HLA
types, survival was 50% for incompatibles versus 74% for
compatibles (n = 118, OR = 2.91, P = .015).
Other Variables. Cox regression was performed for
codon 125 nonidentity together with all 8 of the patient
characteristics listed in Table 2 serving as covariate risk vari-
ables for survival. For overall survival, the multivariate
Kaplan-Meier plots of overall survival probability for groups of patients who were either identical or nonidentical with their HLA-matched sibling
bone marrow transplantation donor at CD31 codon 125 (A-C) or codon 563/670 (D-F). For each graph, the y axis shows overall survival probability
(range, 0-1.0) and the x axis shows days of survival (range, 0-1431 days). Curves for the CD31 identicals are indicated by the “0” tick marks and for
the nonidenticals by the “1” tick marks; each tick mark on a curve represents a censored observation for a member of that group. The comparison
groups are: A, All HLA types, codon 125 identical (n = 65) versus nonidentical (n = 55), hazard ratio (hr) = 1.07, 95% conﬁdence interval (CI) =
1.00-1.14, P = 0.036. B, HLA-A2+ patients, codon 125 identical (n = 37) versus nonidentical (n = 25), hr = 1.06, 95% CI = 0.98-1.16, P = .157. C,
HLA-B44–like patients, codon 125 identical (n = 28) versus nonidentical (n = 24), hr = 1.03, 95% CI = 0.93-1.14, P = .589. D, All HLA types, codon
563/670 identical (n = 66) versus nonidentical (n = 52), hr = 2.58, 95% CI = 1.33-4.99, P = .005. E, HLA-A2+ patients, codon 563/670 identical (n =
38) versus nonidentical (n = 23), hr = 3.51, 95% CI = 1.47-8.38, P = .005. F, HLA-B44–like patients, codon 563/670 identical (n = 28) versus non-
identical (n = 24), hr = 2.63, 95% CI = 0.90-7.71, P = .078.
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analysis (Table 5) showed codon 125 nonidentity to have the
highest level of statistical signiﬁcance (hr = 1.09, P = .012) as
an independent risk factor. In similar multivariate analysis
for disease-free survival, codon 125 nonidentity was again a
signiﬁcant independent risk factor (hr = 1.08, P = .014), as
was pretransplantation risk category (hr = 2.33, P = .011).
Parallel multivariate analysis of codon 563/670 together
with the 8 listed patient characteristics showed similar
results. For overall survival (Table 6), nonidentity at CD31
codon 563/670 was a statistically significant independent
risk factor (hr = 3.25, P = .001), as was adulthood. For dis-
ease-free survival, multivariate analysis with codon 563/670
nonidentity again showed it to be a signiﬁcant independent
risk factor (hr = 2.91, P = .001), as was pretransplantation
risk category (hr = 2.20, P = .019).
Chronic GVHD
Among the 99 patients surviving >100 days posttrans-
plantation, severe or extensive chronic GVHD occurred in
22.4% of codon 125 identical versus 24.4% of codon 125
nonidentical BMT and in 21.7% of codon 563/670 identical
versus 27.0% of codon 563/670 nonidentical patients. Nei-
ther of these differences was statistically signiﬁcant (P > .626).
Relapse
Kaplan-Meier failure estimates were plotted (not
shown) for time to relapse as a function of CD31 noniden-
tity and compared under Cox regression. Relapse of original
disease occurred slightly earlier (hr = 1.06, P = .259) among
CD31 codon 125 nonidentical BMT than among identical
BMT. Relapse rate data and analysis were similar for codon
563/670 nonidentity (hr = 2.14, P = .159). Although CD31
nonidentity at codon 563/670 showed a stronger trend for
earlier relapse than did nonidentity at codon 125, neither
was statistically signiﬁcant.
DISCUSSION
In this single-center prospective study of HLA-matched
sibling BMT, we report for the ﬁrst time that CD31 codon
125 or codon 563/670 nonidentity between donor and
recipient is a signiﬁcant risk factor for overall survival and
for disease-free survival but not for relapse or for chronic
GVHD. We also show the ﬁrst evidence that codon 563/670
nonidentity is a significant risk factor for severe (grade
III/IV) acute GVHD, and we confirm the risk that codon
125 nonidentity poses for severe acute GVHD.
The population genetics of CD31 polymorphism seen in
the present study are consistent with previous reports [8,10].
Alleles of codon 125 had gene frequencies of L = .55 and V =
.45, codon 563 allele frequencies were S = .52 and N = .48,
and codon 670 allele frequencies were R = .52 and G = .48.
Because of their complete linkage disequilibrium, the
563S/670R pairing and the 563N/670G pairing were each
treated as single genetic entities designated codon 563/670.
Linkage disequilibrium between alleles at codon 125 and at
codon 563/670, though substantial, was not complete, and
therefore analysis of codon 125 nonidentity effects was car-
ried out separately from those of codon 563/570.
CD31 nonidentity at either codon 125 or codon
563/670 was observed to be a signiﬁcant independent risk
factor for severe acute GVHD when tested in multivariate
Table 5. CD31 Codon 125 Nonidentity in Cox Regression for Overall Survival Risk Factors*
Risk Factor Hazard Ratio Standard Error P > |z| 95% Confidence Interval
Codon 125 nonidentity 1.09 0.38 0.012 1.02-1.17
HLA-A2+ 1.33 0.46 0.401 0.68-2.62
B44-like+ 0.75 0.26 0.400 0.38-1.47
Adulthood 2.17 0.91 0.064 0.96-4.92
Pretransplantation risk category 1.97 0.69 0.051 1.00-3.91
Recipient-donor sex difference 1.24 0.18 0.141 0.93-1.64
Diagnosis 0.84 0.12 0.214 0.64-1.10
Ethnic group 1.05 0.22 0.820 0.69-1.59
GVHD prophylaxis 1.00 0.00 0.242 1.00-1.01
*Number of observations = 120; χ2 (8) = 16.34; log likelihood = –163.28; probability > χ2 = 0.060. GVHD indicates graft-versus-host disease. 
Table 6. CD31 Codon 563/670 Nonidentity in Cox Regression for Overall Survival Risk Factors*
Risk Factor Hazard Ratio Standard Error P > |z| 95% Confidence Interval
Codon 563/670 nonidentity 3.25 1.17 0.001 1.61-6.58
HLA-A2+ 1.52 0.53 0.227 0.77-3.01
HLA-B44–like+ 0.73 0.25 0.355 0.38-1.42
Adulthood 2.49 1.11 0.040 1.04-5.98
Pretransplantation risk category 1.89 0.67 0.072 0.95-3.77
Recipient-donor sex difference 1.23 0.18 0.145 0.93-1.64
Diagnosis 0.79 0.12 0.109 0.59-1.05
Ethnic group 0.98 0.20 0.935 0.66-1.47
GVHD prophylaxis 1.00 0.00 0.292 1.00-1.11
*Number of observations = 118; χ2 (8) = 21.14; log likelihood = –160.00; probability > χ2 = 0.012. GVHD indicates graft-versus-host disease. 
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analysis with other patient characteristics, including several
(eg, age group, pretransplantation risk category, GVHD
prophylaxis) generally considered predictive of acute
GVHD. These other factors showed trends for risk as
expected, but they did not reach statistical significance.
Comparison of the current CD31 results with those of the
3 previous reports of CD31 and acute GVHD is made difﬁ-
cult by substantial differences in study design and differ-
ences in GVHD rates. For example, the 2 reports evaluat-
ing nonidentity at codon 125 retrospectively selected
patients on the basis of grade of acute GVHD, whereas the
single study describing codon 563/670 evaluated GVHD
incompatibility rather than nonidentity and also compared
grade 0 to any (ie, grade I-IV) acute GVHD rather than to
severe acute disease. Nevertheless, some patterns can be
discerned. First, for direct comparison to Behar et al. and
Nichols et al., we examined severe (grade III/IV) acute
GVHD versus no (grade 0) GVHD. Among patients of any
HLA type, the risks from codon 125 nonidentity in this
report (OR = 9.30, P = .030) and in Behar et al. (OR = 8.93,
P = .002) were signiﬁcant and consistent, whereas Nichols
et al. showed only a trend (OR = 1.30, P = .36) in the same
direction. It is possible that the lesser effect seen by Nichols
et al. may be attributable to the heterogeneity inherent in
their multicenter study (eg, center-to-center variation in
therapeutic protocols, in acute GVHD rates, or in assign-
ment of grade of GVHD) [23]. Conversely, among only
HLA-A2+ patients, Nichols et al. observed a signiﬁcant risk
(OR = 2.67, P = .03) for codon 125 nonidentity that would
be consistent with the trend (OR = 6.39, P = .097) seen in
the current report. The smaller size of our HLA-A2+ popu-
lation and the lower frequency of severe acute GVHD may
account for the differences in levels of statistical signifi-
cance. Increasing the number of our HLA-A2+ patients by
including grade I as well as grade 0 in the group without
severe disease improved the P value, as it did for all com-
parisons. Thus, although Nichols et al. differ from Behar et
al. and this report regarding the speciﬁcs of a relationship
between codon 125 nonidentity and severe acute GVHD
(ie, is HLA-A2+ a necessary condition to establish risk?), the
disagreements are about which trends achieve statistical sig-
niﬁcance but not about the direction of differences. Second,
for comparison to Maruya et al., we examined the subgroup
they showed had a significant codon 563/670 effect, ie,
patients with B44-superfamily types. We were unable to
conﬁrm their ﬁnding that incompatibility at codon 563/670
was a signiﬁcant risk factor for any acute GVHD (grade I-
IV versus grade 0) among patients with B44-like types. Our
data did, however, show 563/670 nonidentity to be a
signiﬁcant risk factor for severe acute GVHD (grade III/IV
versus grade 0/I) among B44-like patients as well as among
patients of all HLA types and among HLA-A2+ patients.
These last data are difficult to reconcile with the results
from the substantially different parameters used by Maruya
et al. Those authors did not study nonidentity nor report
data for patients of all HLA types; and among their HLA-
A2+ patients, 563/670 incompatibility did not increase risk
for grade I-IV versus grade 0 GVHD. Some of the differ-
ences between the current report and that of Maruya et al.
might be attributable to substantial differences in GVHD
rates or GVHD diagnosis (eg, 67% of our patients had
grade 0 GVHD versus only 45% in the Japanese multicen-
ter study) or in ethnic backgrounds of patient populations.
A more detailed comparison between the 2 reports would
appear to be of questionable value at this point, however,
because of the substantive differences in deﬁning clinically
relevant GVHD groupings (ie, severe rather than all acute
GVHD), mismatch parameters (ie, nonidentity rather than
incompatibility), and lack of further published clinical
information about their patients. Still, both reports share
the conclusion that CD31 codon 563/670 appears impli-
cated as a risk factor in acute GVHD.
Acute GVHD rates have commonly been used to study
clinical relevance of putative mHags, particularly in the set-
ting of HLA-identical sibling BMT, where major histocom-
patibility complex (MHC) incompatibility can be completely
excluded. Although patients at opposite ends of the acute
GVHD spectrum can readily be distinguished, assigning an
exact grade of disease may be much more challenging, and
the proper cutoff for comparing clinically signiﬁcant versus
nonsignificant grades can be difficult to define. We felt it
was justifiable to expand the comparison group without
severe disease by including grade I patients because the clin-
ical distinction between grade 0 and grade I is difﬁcult and
often tenuous, and because at our center the overall survival
rates of grade 0 and of grade I patients are not signiﬁcantly
different. In our data, every comparison of severe acute dis-
ease versus the broader (grade 0/I) minimal disease group
yielded greater statistical signiﬁcance than did the cognate
comparisons using only grade 0 as the group without severe
disease. In contrast, broadening the group with severe dis-
ease to also include grade II diluted but did not abolish the
acute GVHD risk from CD31 nonidentity. These results
suggest that comparing patients with severe acute GVHD
with those with minimal acute GVHD may be the most
informative clinical groupings for future study.
Given the preceding concerns about comparing acute
GVHD rates, it is appropriate to consider other BMT out-
come measures to assess clinical impact of putative mHags.
For overall survival and for disease-free survival, we
observed that nonidentity at codon 125 or at 563/670 was a
signiﬁcant risk factor. The higher hazard ratios and smaller
P values seen for codon 563/670 effects on survival suggest
that this codon may be exerting the primary impact of
CD31 nonidentity, whereas the codon 125 impact may be a
secondary phenomenon due to linkage disequilibrium
between alleles at the 2 codons. Resolution of this issue will
require additional patient-donor pairs in which CD31 non-
identity occurs at only 1 (ie, either, but not both) of the
2 codons. With respect to HLA restriction, we saw some
modest differences of CD31 nonidentity survival effect
among HLA-A2+ patients, patients with B44-like types, and
patients with all HLA types. This is consistent with the
observation by Maruya et al. that, among their patients with
B44-like types, there was a trend for poorer survival (not
further deﬁned but presumably overall survival at the time
they closed their study) of codon 563/670 incompatibles
compared to compatibles (69% versus 78%, P = NS). They
did not report survivals for all HLA types or for HLA-A2+
patients. To facilitate comparison to that report, we calcu-
lated the same survival parameter for our B44-like patients
and observed a similar trend in which incompatibles at
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codon 563/670 had 60% survival versus 76% for compati-
bles (OR = 2.07, P = .318). Among our patients of all HLA
types, the codon 563/670 incompatibility effect persisted
(50% versus 74%, OR = 2.91) and reached statistical signiﬁ-
cance (P = .015). As with the HLA-dependent differences we
observed in analysis of the CD31 effect on acute GVHD, at
present we believe that the HLA-dependent differences in
survival we observed were not large enough to draw any
conclusion about HLA restriction without studying a much
larger number of patients.
Although the data presented do not deﬁne any speciﬁc
mechanism of action, the impact of CD31 nonidentity on
both severe acute GVHD and survival is consistent with a
clinically signiﬁcant mHag role for this polymorphic adhe-
sion molecule. It is reasonable to attribute at least some of
the observed effects to the current concept of host mHag
peptides, presented on MHC molecules, as cytotoxic T lym-
phocyte (CTL) targets. In vitro model systems to detect
such CTLs in human BMT patients have been deﬁned for
the putative mHags HA-1 and HY [24]. For several reasons,
however, this model system may not fully explain all of the
BMT complications likely attributable to mHags. For exam-
ple, the most vigorous CTL responses were for HY, an
mHag with unclear clinical signiﬁcance as a risk factor for
GVHD in humans [2,9,24-27]; and, in mice, in vitro CTL
responses many not necessarily correlate with in vivo
mHag-induced GVHD [28]. Furthermore, with respect to
HLA restriction in the CTL model, Maruya et al. con-
cluded that a peptide from CD31 exon 12 (ie, the exon con-
taining the codon 670 polymorphism) had a good ﬁt in the
peptide binding groove of HLA antigens with the B44-like
supermotif. This would be consistent with their observation
that codon 563/670 incompatibility correlated with acute
GVHD among patients with HLA-B44–like types. Our data
showing codon 563/670 nonidentity to be a signiﬁcant risk
factor for severe acute GVHD and for survival in patients of
all HLA types would suggest the presence of either addi-
tional, as-yet-unspecified HLA restriction elements or
degeneracy at the MHC or T-cell level. This type of
promiscuous recognition of allopeptide presented on differ-
ent MHC molecules has been previously described [29,30].
In addition to acute GVHD from the classic mechanism of
donor CTL attacking host foreign mHag, other alloimmune
processes also may affect BMT outcome. For example, even
small numbers of residual host T cells could attack mHag
on donor hematopoietic cells and thus increase susceptibility
to infection or relapse. Further, BMT outcome can be
affected by graft-versus-leukemia (GVL) effects seen in the
setting of HLA-incompatible transplants and likely related
to natural killer (NK) cells (ie, recipient lacks a class I major
histocompatibility antigen present in the donor) [31-33].
Because the full repertoire of NK recognition is not yet
known and can involve peptides bound by HLA class I, it
may be premature at this time to focus on mHag incompati-
bilities only in the classic GVHD direction [33-35]. The use
of CD31 nonidentity rather than incompatibility (in the
GVHD direction) as a parameter for possible mHag effect is
thus a reflection of our lack of knowledge of the balance
between classic mHag-related CTL mechanisms and other
possible immune mechanisms that could affect outcomes in
human BMT.
CD31 nonidentity was also studied for its impact on
relapse and on chronic GVHD. Although some trends were
observed, none attained statistical signiﬁcance as risk factors
in these additional BMT outcome measures. This observa-
tion suggests that acute and chronic GVHD may be biologi-
cally different processes rather than simply different clinical
manifestations of a single pathogenetic entity. Considering
that studies [36] have correlated GVL effects with chronic
rather than acute GVHD, the lack of reduction in chronic
GVHD in CD31-identical transplantation is consistent with
a lack of increase in relapse rate despite a decrease in acute
GVHD risk.
Overall, this single-center prospective study demon-
strates that in HLA-identical sibling BMT with unmanipu-
lated bone marrow, CD31 nonidentity between donor and
recipient is a signiﬁcant independent risk factor for survival
and for severe acute GVHD. The risk may be primarily
from codon 563/670 nonidentity, with linkage disequilib-
rium explaining or contributing to the risk observed for
codon 125 nonidentity. Although some differences among
subgroups of different HLA types were observed, these
were not considered sufficient to prove any specific HLA
restriction.
Insight into mHag GVHD risk could result in risk-
adopted strategies for acute GVHD prevention in which
patients who are at high risk could undergo aggressive pro-
phylaxis, including T-cell depletion, whereas patients at
low risk could receive lowered immune suppression. In
addition, CD31 identity could aid in donor selection for
those patients with more than 1 HLA-matched sibling
available, or for the selection among possible unrelated
donors if similar results of mHag GVHD and/or survival
risk are observed in the clinical setting of matched unre-
lated BMT.
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